Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

456
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
456
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.5K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

515
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
515

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physiology Still Matters: Lessons From FAVOR III China.

Journal of the American College of Cardiology·2026
Same author

Fractional flow reserve in coronary computed tomography angiography: An expert consensus document of the society of cardiovascular computed tomography (SCCT) and the society for cardiovascular angiography and interventions (SCAI). Endorsed by the American college of cardiology (ACC).

Journal of cardiovascular computed tomography·2026
Same author

Editorial: FFR/iFR discordance in AS - More a physiologic than anatomic cause?

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

CalShock: beyond the shock team, building on California's cardiogenic shock system of care.

Heart failure reviews·2026
Same author

Prognosis for Isolated Coronary Artery Ectasia: Hope for the Best, Expect the Worst.

Circulation. Cardiovascular interventions·2026
Same author

How can we further optimize coronary stent placement?

Expert review of medical devices·2025

Related Experiment Video

Updated: Mar 20, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K

Why we need intravenous antiplatelet agents.

Jeffrey M Tyler1, Ryan Jw Burris1, Arnold H Seto1

  • 1Department of Cardiology, Long Beach Veteran's Affairs Medical Center, 5901 East 7th Street, Long Beach, CA 90822, USA.

Future Cardiology
|June 4, 2016
PubMed
Summary

Intravenous antiplatelet agents, like cangrelor, offer improved platelet inhibition during percutaneous coronary intervention (PCI) compared to oral dual antiplatelet therapy (DAPT). Their use can reduce the risk of periprocedural thrombosis.

Keywords:
cangrelorclopidogrelglycoprotein IIb/IIIa inhibitorsintravenous antiplatelet agentsprasugrelticagrelor

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dual antiplatelet therapy (DAPT) with oral ADP-receptor antagonists and aspirin is standard for percutaneous coronary intervention (PCI).
  • Oral ADP-receptor antagonists have limitations including unpredictable platelet inhibition and prolonged effects, complicating pre-PCI loading decisions.

Purpose of the Study:

  • To review the current state of peri-PCI DAPT.
  • To demonstrate the benefits of intravenous antiplatelet agents in reducing periprocedural thrombosis.

Main Methods:

  • Review of current literature on peri-PCI DAPT.
  • Examination of the role of intravenous antiplatelet agents, including glycoprotein IIb/IIIa inhibitors (GPI) and cangrelor.

Main Results:

  • Intravenous agents address shortcomings of oral ADP-receptor antagonists.
  • The FDA approved cangrelor in June 2015 for preventing thrombotic events post-coronary stenting.

Conclusions:

  • Selective use of GPIs and intravenous ADP-antagonist agents can reduce periprocedural thrombosis risk.
  • Intravenous antiplatelet therapy offers a valuable alternative for DAPT during PCI.